Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Alpha-glucosidase Inhibitor
(+)-Afzelechin is an alpha-glucosidase inhibitor derived from the rhizomes of Bergenia ligulata. It demonstrates an ID50 value of 0.13 mM, indicating its potency in inhibiting alpha-glucosidase activity. This compound effectively delays carbohydrate absorption, thereby reducing postprandial hyperglycemia and hyperinsulinemia. It serves as a valuable tool for research in metabolic disorders and glycemic control. -
α-glucosidase Inhibitor
Ganoderol B is a potent inhibitor of α-glucosidase, exhibiting significant enzymatic inhibition with an IC50 value of 48.5 μg/mL (119.8 μM). This compound is primarily utilized in research applications related to carbohydrate metabolism and glucose regulation, making it a valuable tool in studies of diabetes and postprandial hyperglycemia. Researchers may leverage Ganoderol B to explore mechanisms of glycemic control and to develop therapeutic strategies targeting α-glucosidase. -
α-Glucosidase Inhibitor
(-)-Pinoresinol 4-O-glucoside serves as a potent α-glucosidase inhibitor, exhibiting an IC50 value of 48.13 µM. This compound promotes cell migration and early differentiation of pre-osteoblasts while enhancing the protein levels of BMP2, phosphorylated Smad1/5/8, and RUNX2. Additionally, it demonstrates protective effects against oxidative stress, hyperglycemia, and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside is a valuable reagent for investigating osteoporosis and periodontal disease. -
α-Glucosidase Inhibitor (AGI)
α-Glucosidase-IN-11 is a potent competitive inhibitor of α-glucosidase, exhibiting an IC50 value of 0.56 μM. This compound selectively binds to tryptophan residues in the enzyme, influencing its protein folding and activity. α-Glucosidase-IN-11 has potential applications in the regulation of carbohydrate metabolism and blood glucose control, making it a valuable tool for diabetes research and therapeutic development. -
Glycosidase Inhibitor
N-Methylmoranoline is a potent α-glucosidase inhibitor that modulates carbohydrate metabolism by interfering with enzyme activity. This compound demonstrates significant potential in research related to diabetes management and metabolic disorders by reducing glucose absorption. It is utilized in studies exploring glycemic control and the pharmacological effects of glycosidase inhibition. -
Glucosidase Inhibitor
Glucocerebrosidase-IN-1 hydrochloride is a potent and selective inhibitor of glucocerebrosidase (GCase), demonstrating an IC50 of 29.3 μM and a Ki of 18.5 μM. This compound is relevant for research applications concerning Gaucher disease and Parkinson's disease, as it influences cellular metabolism of glucocerebrosides. Its selective inhibition makes it a valuable tool for studying the biochemical pathways associated with these conditions. -
α-glucosidase Inhibitor
Carpachromene is a potent inhibitor of the α-glucosidase enzyme. It has been shown to ameliorate insulin resistance in HepG2 cells by modulating the IR/IRS1/PI3K/Akt/GSK3/FoxO1 signaling pathway. This compound is valuable for researching metabolic disorders and potential therapeutic strategies for diabetes management. -
α-Glucosidase Inhibitor
Casuarictin is a potent α-glucosidase inhibitor, exhibiting competitive inhibition with an IC50 of 0.21 μg/mL. It also acts as an inhibitor of presenilin stabilization factor-like protein (PSFL). This compound is valuable for research applications related to Alzheimer's disease and metabolic disorders, providing insights into therapeutic strategies targeting carbohydrate metabolism. -
β-glucosidase Inhibitor
Validamine is a competitive inhibitor of β-glucosidase, demonstrating pH-dependent and dose-dependent inhibition with an IC50 value of 2.92 mM. Its maximum inhibitory effect occurs at the enzyme's optimal pH, making it a valuable tool for studying β-glucosidase function and regulation. This compound can be utilized in research applications focused on carbohydrate metabolism and related pathways. -
α-Glucosidase/α-Aamylase Inhibitor
Diphlorethohydroxycarmalol is a phlorotannin that serves as an inhibitor of α-glucosidase and α-amylase, exhibiting IC50 values of 0.16 mM and 0.53 mM, respectively. This compound demonstrates significant anti-diabetic activity, making it relevant for research focused on glucose metabolism and diabetes management. Its mechanism of action highlights its potential application in developing therapeutic strategies for metabolic disorders. -
α-glucosidase Inhibitor
p-Hydroxyphenethyl trans-ferulate is an α-glucosidase inhibitor known for its anti-hyperglycemic properties, exhibiting an IC50 value of 19.24 ± 1.73 µM against yeast α-glucosidase. This compound also demonstrates antioxidant and anti-inflammatory activities, making it a valuable tool in the study of metabolic disorders. Additionally, p-Hydroxyphenethyl trans-ferulate has shown potential in inhibiting cancer cell proliferation and modulating serotonergic activity, supporting its application in cancer and neurological research. -
Endoplasmic Reticulum α-Glucosidases I and II Inhibitor
EB-0156 is a potent inhibitor of endoplasmic reticulum α-glucosidases I and II, exhibiting IC50 values of 0.0479 μM and less than 0.001 μM, respectively. Derived from valiolamine, this compound demonstrates broad-spectrum antiviral activity. EB-0156 is valuable for research focused on developing therapeutic agents against both existing and emerging viral pathogens. -
Glycosidase Inhibitor
1,3-Dipalmitoleoyl glycerol is an α-glucosidase inhibitor with significant biological activity derived from sea cucumber viscera. This compound demonstrates varying degrees of inhibitory effects on α-glucosidase from diverse sources, making it valuable for research into carbohydrate metabolism and related disorders. Its application in studying glycosidase functions can provide insights into metabolic pathways and potential therapeutic targets. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-6 is a competitive inhibitor of α-glucosidase, exhibiting an IC50 of 5.69 µM. This compound demonstrates potential anti-diabetic activity by modulating carbohydrate metabolism. It is applicable in research focused on diabetes treatment and metabolic disorders. -
α-Glucosidase Inhibitor
Flaccidoside III is a triterpenoid compound that functions as an α-glucosidase inhibitor, exhibiting an IC50 value of 256.7 μM. It demonstrates significant potential for antioxidant and antidiabetic activities, making it a valuable reagent in metabolic research and studies aimed at understanding glucose regulation. Its effects on α-glucosidase modulation contribute to its implications in diabetes management research. -
α-Glucosidase Inhibitor
3-Oxo-hop-22(29)-ene is a potent inhibitor of α-glucosidase, predominantly affecting yeast enzymes. This compound exhibits moderate inhibitory effects on the viability of Trichomonas cruzi and Leishmania mexicana, suggesting its potential as a therapeutic agent against these pathogens. Additionally, 3-Oxo-hop-22(29)-ene displays marginal anti-inflammatory activity, highlighting its multifaceted biological applications in research. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-4 is a reversible, mixed-type inhibitor of α-glucosidase, exhibiting an IC50 value of 12.98 μM. This compound serves as a valuable tool for studying carbohydrate metabolism and its associated disorders, including diabetes and obesity. Its ability to modulate α-glucosidase activity makes it suitable for research into therapeutic strategies targeting glycemic control. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-12 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 10.20 μM. This compound effectively modulates carbohydrate digestion and absorption, making it valuable for research on metabolic disorders such as type 2 diabetes and obesity. Its use in biochemical assays provides insights into enzymatic activity and potential therapeutic strategies. -
α-glucosidase/Acetylcholinesterase Inhibitor
7β-Hydroxybufalin is a bufadienolide that acts as a potent inhibitor of α-glucosidase and acetylcholinesterase. Isolated from the venom of Bufo bufo gargarizans, this compound demonstrates significant biological activity relevant to the modulation of carbohydrate and neurotransmitter metabolism. 7β-Hydroxybufalin is utilized in research applications focused on metabolic disorders and neurodegenerative diseases. -
α-glucosidase inhibitor
α-Homonojirimycin is a potent inhibitor of α-glucosidase, an enzyme involved in carbohydrate metabolism. By blocking α-glucosidase activity, it effectively modulates glucose absorption, making it a valuable compound for research in diabetes and metabolic disorder studies. Its inhibitory properties are also applicable in exploring the roles of glycosidases in various biological processes. -
α-Glucosidase Inhibitor
4-Ethoxy-5,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one is a naphthalene derivative that functions as a weak α-glucosidase inhibitor. This compound, which can be isolated from the leaves of Cyclocarya paliurus, is relevant in the study of diabetes management. Its inhibitory activity on α-glucosidase suggests potential applications in carbohydrate metabolism research and glycemic control studies. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-16 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 3.28 μM. This compound effectively lowers blood glucose levels in Streptozotocin-induced diabetic rats, demonstrating significant antidiabetic properties. Its use in research facilitates the exploration of therapeutic strategies for managing diabetes and related metabolic disorders. -
α-glucosidase Inhibitor
α-Glucosidase-IN-54 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 0.011 mM. This compound, derived from Syzygium jambos, is valuable for research focused on glucose metabolism and diabetes management. Its inhibitory action makes it a useful tool for studying the mechanisms of carbohydrate digestion and potential therapeutic interventions for hyperglycemia. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-29 is a potent inhibitor of α-glucosidase, displaying an IC50 value of 1.21 μM and a Ki value of 1.80 μM. This compound is primarily utilized in research focused on diabetes and associated metabolic disorders, where modulation of carbohydrate absorption is critical. Its mechanistic action allows for potential exploration in understanding the therapeutic effects against glycemic control and related physiological impacts. -
Endoplasmic Reticulum α-Glucosidases I and II inhibitor
EB-0176 is a potent inhibitor of endoplasmic reticulum α-glucosidases I and II, exhibiting IC50 values of 0.6439 μM and 0.0011 μM, respectively. This N-substituted derivative of valiolamine demonstrates broad-spectrum antiviral activity, positioning it as a valuable tool for research into antiviral agents targeting both existing and emerging viruses. Its ability to inhibit key glycosylation processes makes it significant for studies in virology and therapeutic development. -
Alpha-Glucosidase Inhibitor
Vitexin-2''-O-glucoside is a selective inhibitor of alpha-glucosidase, primarily extracted from flavonoids in hawthorn leaves. It reversibly inhibits α-glucosidase activity at the brush border of the small intestine, demonstrating a potent inhibitory effect. This compound is widely utilized in research related to type 2 diabetes and may serve as a promising candidate for therapeutic development in glycemic control. -
α-Glucosidase Inhibitor
PBI-6DNJ is a potent α-glucosidase inhibitor that functions as a multivalent glycosidase inhibitor. It demonstrates significant inhibitory activity against mouse α-glucosidase, with an affinity constant (Ki) of 0.14 μM. The compound also exhibits notable hypoglycemic effects, making it a valuable tool for research related to type 2 diabetes. -
α-Glucosidase Inhibitor
16-Oxoserratenediol is a serratene-type triterpenoid that functions as an α-glucosidase inhibitor, demonstrating an inhibition rate of 43.93% at a concentration of 100 μM. This compound is derived from Lycopodium cernuum L. and is primarily utilized in research related to diabetes management and metabolic disorders. Its mechanism of action contributes to the regulation of carbohydrate metabolism, making it a valuable tool for studying glycemic control in various biological contexts. -
α-glucosidase Inhibitor
Deacylhericene is an α-glucosidase inhibitor that demonstrates a potent inhibitory effect with an IC50 of 12.5 μM. This compound functions by effectively reducing the activity of α-glucosidase, making it a valuable reagent for studying carbohydrate metabolism. Its application is particularly relevant in diabetes research and the exploration of glycemic control mechanisms. -
α-Glucosidase Inhibitor
2,3-Indolobetulonic acid functions as an α-glucosidase inhibitor, exhibiting an IC50 of 1.8 µM. This triterpenoid compound is significant in research related to glucose metabolism and diabetes management. It is valuable for studies focusing on carbohydrate digestion and its modulation within metabolic pathways. -
α-Glucosidase Inhibitor
(-)-6β-Hydroxy-5β,8β,9β,10α-cleroda-3,13-dien-16,15-olid-18-oic acid serves as a potent α-Glucosidase inhibitor, demonstrating an IC50 value of 577.7 µM. This compound is valuable in research focused on carbohydrate metabolism and the management of postprandial hyperglycemia. Its ability to modulate α-glucosidase activity makes it a useful tool in studies related to diabetes and metabolic disorders. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-38 is a potent inhibitor of α-glucosidase, with an IC50 value of 12.44±0.38 μM. This compound is significant for its role in the management of Diabetes Mellitus (DM) by reducing carbohydrate absorption in the intestines. It is useful for research applications focused on metabolic disorders and the development of diabetes therapies. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-24 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 451 μM. This compound is derived from the plant Swertia kouitchensis and is primarily used in research to study carbohydrate metabolism and its implications in conditions such as diabetes and obesity. Its inhibitory action on α-glucosidase makes it a valuable tool for exploring therapeutic strategies targeting metabolic disorders. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-113 is a specific inhibitor of α-glucosidase, exhibiting an IC50 of 17.52 μM. This compound demonstrates antiglycating properties and effectively inhibits the formation of advanced glycation end-products. Its applications include research into type 2 diabetes and related metabolic disorders. -
α-Glucosidase Inhibitor
N-Formyldehydroanonaine is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 104.6 μM against yeast α-glucosidase. This compound is useful for research into diabetes mellitus, providing insights into the management of postprandial blood sugar levels through inhibition of carbohydrate breakdown. -
α-glucosidase Inhibitor
Prunetin 5-O-β-D-glucopyranoside is an isoflavone that functions as a potent uncompetitive inhibitor of α-glucosidase, exhibiting an IC50 of 56.05 μg/mL. This compound is derived from extracts of Potentilla astracanica and plays a significant role in modulating carbohydrate metabolism. It is particularly relevant for research applications focused on type-2 diabetes and the management of postprandial hyperglycemia. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-25 is a competitive inhibitor of α-glucosidase, exhibiting an IC50 value of 1.19 μM. This compound serves as a valuable tool in anti-diabetic research by inhibiting carbohydrate absorption and regulating postprandial blood glucose levels. Its ability to modulate α-glucosidase activity makes it a promising candidate for the development of therapeutic strategies targeting diabetes management. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-14 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 5.22 μM. This compound is valuable for studying carbohydrate metabolism and related disorders, particularly in the context of diabetes management. Its ability to inhibit α-glucosidase makes it a useful tool in pharmacological research aimed at developing therapies that modulate glucose absorption and metabolism. -
α-glucosidase Inhibitor
N-(E)-Caffeoyldopamine is an α-glucosidase inhibitor derived from Clerodendranthus Spicatus, demonstrating an inhibitory activity of 53.73% against the enzyme. This compound has significant potential for applications in diabetes research, where it can be utilized to explore mechanisms of glucose metabolism and regulation. Its role in modulating α-glucosidase activity makes it a valuable tool for studying carbohydrate absorption and related metabolic disorders. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-70 is a potent α-glucosidase inhibitor with an IC50 of 31.1 μM, derived from the traditional Chinese herbal medicine Swertia mussotii. This compound is valuable for investigating the modulation of carbohydrate metabolism, particularly in the context of diabetes research. Its inhibitory action on α-glucosidase makes it a suitable candidate for further studies exploring therapeutic strategies to manage postprandial hyperglycemia. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-111 is a selective inhibitor of α-glucosidase, demonstrating an IC50 of 34.99 μg/mL. In addition to its inhibitory effects on α-glucosidase, it exhibits strong antioxidant properties, effectively scavenging DPPH and ABTS free radicals with IC50 values of 5.33 and 5.84 μg/mL, respectively. This compound is valuable for research focused on type 2 diabetes and related metabolic disorders, making it a useful tool for studying glycemic control and oxidative stress mechanisms. -
Alpha-glucosidase Inhibitor
Valibose is an alpha-glucosidase inhibitor that plays a crucial role in regulating carbohydrate metabolism. It has been shown to improve metabolic disorders related to glucose and lipid levels, as well as alleviate nephropathy in Streptozotocin-induced diabetic rat models. This compound is valuable for research focused on diabetes and associated metabolic conditions. -
α±-Glucosidase Inhibitor
Chrysin 6-C-arabinoside 8-C-glucoside is an α±-glucosidase inhibitor that demonstrates significant potential in the management of type 2 diabetes. By inhibiting α-glucosidase activity, this compound can effectively reduce carbohydrate digestion and absorption, potentially leading to improved glycemic control. Its biological activity makes it a valuable tool for research into metabolic disorders and the development of antidiabetic therapies. -
α-glucosidase Inhibitor
α-Glucosidase-IN-22 is a benzimidazole derivative that serves as a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 0.64 μM. This compound demonstrates significant anti-diabetic properties, making it a promising candidate for research in type 2 diabetes mellitus (T2DM). Its ability to modulate carbohydrate digestion positions α-Glucosidase-IN-22 as a valuable tool in glucose metabolism studies and diabetes management investigations. -
Glycosidase Inhibitor
L-Afegostat (5-epi-Isofagomine) is a glycosidase inhibitor that targets β-Glucosidase, exhibiting enzyme inhibition with a Ki of 30 μM. This iminosugar plays a significant role in carbohydrate synthesis and is valuable for studying glycosidase-related metabolic processes. It is particularly useful in research focused on enzyme regulation and glycosylation mechanisms. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-43 is a potent α-glucosidase inhibitor with an IC50 value of 4.32 μM, demonstrating significant hypoglycemic activity. This compound exhibits low toxicity in normal mouse fibroblasts and shows efficacy in vivo, effectively rescuing streptozotocin-induced diabetic rats. α-Glucosidase-IN-43 is valuable for investigating postprandial hyperglycemia and related metabolic disorders in diabetes research. -
α-glucosidase Inhibitor
Quercetin 3'-methoxy-3-O-α-L-arabinofuranoside is an α-glucosidase inhibitor, derived from the leaves and twigs of Fagus hayatae. This compound demonstrates weak inhibitory activity against α-glucosidase, an enzyme involved in carbohydrate metabolism. It serves as a valuable tool for research in glycemic control and metabolic studies. -
α-Glucosidase Inhibitor
Falandioside B is an α-glucosidase inhibitor with an IC50 of 107.52 μM, effectively modulating carbohydrate metabolism. It exhibits antioxidant activity by scavenging ABTS radical cations, making it relevant for studies on oxidative stress. This compound is primarily utilized in research focused on managing postprandial hyperglycemia and its associated metabolic implications. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-9 is a potent inhibitor of α-glucosidase, exhibiting an IC50 of 55.6 μM. This compound is relevant for research applications focused on type II diabetes, enabling the investigation of carbohydrate digestion and glucose absorption. Through its inhibitory action, α-Glucosidase-IN-9 provides a valuable tool for studying the metabolic implications associated with dysregulated glucose homeostasis. -
Endoplasmic Reticulum α-Glucosidases I/II inhibitor
EB-0150 is a selective inhibitor of endoplasmic reticulum α-glucosidases I and II, exhibiting IC50 values of 0.73 µM and 0.0337 µM, respectively. This N-substituted derivative of valiolamine demonstrates broad-spectrum antiviral activity and can be utilized in research aimed at developing agents against both existing and emerging viral pathogens. Additionally, EB-0150 serves as a versatile click chemistry reagent, possessing an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) with alkyne-containing and DBCO or BCN-labeled molecules.
